| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
The primary biological role of Calcium dextrofolinate is as a reduced folate cofactor. It is the (6R)-isomer of folinic acid, which is the active form in one-carbon transfer reactions. It serves as a substrate for reduced folate carrier (RFC) and is involved in thymidylate and purine synthesis. Its specific molecular targets include enzymes of one-carbon metabolism.
|
|---|---|
| ln Vitro |
In vitro, Calcium dextrofolinate is the active isomer of folinic acid and is used in research applications requiring the biologically active form of reduced folate. It is a drug isomer with defined stereochemistry at two centers. Specific IC50 or EC50 values for biological activity are not available in accessible literature.
|
| ln Vivo |
No specific in vivo efficacy data have been published for Calcium dextrofolinate as a therapeutic agent. It is used as a research compound to study folate metabolism and as a rescue agent in methotrexate therapy. Pharmacokinetic parameters are similar to those of folinic acid.
|
| Enzyme Assay |
No specific receptor binding or enzyme inhibition assays are established for Calcium dextrofolinate. Its characterization relies on analytical methods including HPLC for purity and stereochemical analysis. It is used as a substrate in enzyme assays for one-carbon metabolism enzymes such as thymidylate synthase.
|
| Cell Assay |
No specific cell-based assays are routinely performed for Calcium dextrofolinate. It may be used in cell culture as a folate source for folate-dependent cell lines. Cell proliferation assays in folate-free medium supplemented with Calcium dextrofolinate can be performed to assess its biological activity.
|
| Animal Protocol |
No specific animal protocols are established for Calcium dextrofolinate. General pharmacokinetic studies in rodents could involve intravenous or oral administration followed by plasma sampling and LC-MS/MS analysis to measure folate levels. No published efficacy or safety studies are available.
|
| References |
| Molecular Formula |
C20H22CAN7O7
|
|---|---|
| Molecular Weight |
512.51
|
| Exact Mass |
511.113
|
| CAS # |
115940-48-2
|
| Related CAS # |
(6R)-Leucovorin; 73951-54-9
|
| PubChem CID |
135484650
|
| Appearance |
Light brown to brown solid
|
| LogP |
0.017
|
| tPSA |
226.49
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
35
|
| Complexity |
900
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
O=C(O)CC[C@@H](C([O-])=O)NC(C1=CC=C(NC[C@H]2N(C=O)C3=C(N=C(N)NC3=O)NC2)C=C1)=O.[Ca+2]
|
| InChi Key |
KVUAALJSMIVURS-KZCZEQIWSA-L
|
| InChi Code |
InChI=1S/C20H23N7O7.Ca/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30;/h1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32);/q;+2/p-2/t12-,13+;/m1./s1
|
| Chemical Name |
calcium;(2S)-2-[[4-[[(6R)-2-amino-5-formyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioate
|
| Synonyms |
Calcium (6R)-folinate; Calcium dextrofolinate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: ~2.0 mg/mL (~3.8 mM; ultrasonic and warming and adjust pH to 2 with 1 M HCl and heat to 60°C)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9512 mL | 9.7559 mL | 19.5118 mL | |
| 5 mM | 0.3902 mL | 1.9512 mL | 3.9024 mL | |
| 10 mM | 0.1951 mL | 0.9756 mL | 1.9512 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.